Table 5.
Effect of treatment with T-705 after virus exposure in hamsters challenged with YFV.
| Treatment | Time of start of therapy (h) | Survivors/total | MDD ± S.D. | Serum ALT ± S.D. |
|---|---|---|---|---|
| Saline | −4 | 3/10 | 7.4 ± 1.8 | 188 ± 94 |
| T-705 | −4 | 10/10*** | >21.0 | 75 ± 23** |
| +24 | 10/10*** | >21.0 | 80 ± 32** | |
| +48 | 10/10*** | >21.0 | 84 ± 47** | |
| +72 | 8/10* | 7.0 ± 1.4 | 139 ± 71 | |
| +96 | 6/10 | 6.5 ± 0.6 | 115 ± 82* | |
| +120 | 5/10 | 6.8 ± 0.8 | 157 ± 74 | |
| Ribavirin | −4 | 10/10*** | >21.0 | 110 ± 61* |
T-705 was orally administered twice daily for 8 days at a dose of 400 mg/kg/day and ribavilrin was administered at a dose of 50 mg/kg/day. MDD: mean day of death. S.D.: standard deviation. ALT: serum alanine aminotransferase, in international units per liter.
*
P < 0.05.
**
P < 0.01
***
P < 0.001 as compared with saline-treated controls (Julander et al., 2009).